PATENT ABSTRACTS OF JAPAN

(11) Publication number: 2000026295 A (43) Date of publication of application: 25.01.2000

(51) Int. Cl A61K 31/4415

A61P 9/00, A61P 43/00, A61K 31/675 // C07D213/66, C07D213/67

(21) Application number: 10338077
 (22) Date of filing: 27.11.1998
 (30) Priority: 09.07.1998 US 98 112277

(54) THERAPEUTIC AGENT FOR ISCHEMIC REPERFUSION INJURY AND THERAPEUTIC AGENT FOR CELL DYSFUNCTION INCLUDING CARDIAC INSUFFICIENCY DUE TO ARRHYTHMIA AND CARDIAC INFARCTION

(57) Abstract:

PROBLEM TO BE SOLVED: To obtain a therapeutic agent useful for ischemic reperfusion injury and cell dysfuntion of mammals by including pyridoxal phosphate, pyridoxine, pyridoxal, etc.

SOLUTION: This therapeutic agent is obtained by including a compound selected from (A) pyridoxal-5'-phosphate represented by the formula, (B) pyridoxine, (C) pyridoxal and (D) pyridoxane. The therapeu-

(71) Applicant: UNIV MANITOBA
(72) Inventor: DAARA NARANJAN S

SETTI RAJA

DUCKSHINAM-T CHRISHNAM-T

tic agent is preferably administered in a daily dose of about 1-50 mg based on 1 kg body weight of a patient. The ingredients A to D and a pharmaceutically acceptable carrier (a physiological saline solution, a Ringer's solution, etc.), are contained to afford a pharmaceutical composition. The composition is preferably enterally or parenterally administered. Great effects on treatment of ischemic reperfusion injury and cell dysfunction including cardiac insufficiency due to arrhythmia and cardiac infarction can be produced by properly administering the ingredients A to D.

COPYRIGHT: (C)2000, JPO